EDRN is at the forefront of technology-driven research on the use of biomarkers for the early detection of cancer. By identifying and validat- ing biomarkers, such as novel proteins or changes in gene expression, it is possible to measure an individual’s disease risk, progression of disease, or response to therapy. Ultimately, EDRN research will aid in prevention and in early therapeutic intervention, based on early detection of disease. Researchers with EDRN have been instrumental in identifying and validating markers for many major cancers, such as prostate (protein profiling of BPH, HPIN and IGFb3/br), colon (K-ras mutations in stool and urine).
